Showing 1561-1570 of 1774 results for "".
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRShttps://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an i
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directorshttps://modernod.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/Allegro Ophthalmics announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance. “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of
- Lighthouse Guild Starts Construction on New Technology Centerhttps://modernod.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/Lighthouse Guild has started construction on a Technology Center that will be the largest, premier assistive technology resource in the United States, according to a news release. Designed for people who are visually impaired and for all people who are using technology in order to help them, it i
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i
- Orasis Pharmaceuticals Appoints Industry Veteran Paul Smith as President and Chief Operating Officerhttps://modernod.com/news/orasis-pharmaceuticals-appoints-industry-veteran-paul-smith-as-president-and-chief-operating-officer/2479112/Orasis Pharmaceuticals announced the appointment of Paul Smith as president and chief operating officer (COO). Mr. Smith brings over two decades of leadership in eye care. “I am excited to join Orasis Pharmaceuticals at such a pivotal time in the company’s h
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- FDA Panel Endorses Moderna’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/fda-panel-endorses-modernas-covid-19-vaccine-for-emergency-use/2478678/An FDA advisory panel on Thursday voted 20-0, with one abstention, that the benefits of Moderna’s COVID-19 vaccine mRNA-1273 outweigh its risks in people 18 years and older. The panel backing sets the stage for the FDA to issue an emergency-use authorization (EUA) for the candidate, which i
- FDA Authorizes Regeneron’s Dual COVID-19 Antibody Treatment for Emergency Usehttps://modernod.com/news/fda-authorizes-regenerons-dual-covid-19-antibody-treatment-for-emergency-use/2478587/The FDA has issued an emergency-use authorization (EUA) to Regeneron’s filing for casirivimab and imdevimab to be administered together to treat mild-to-moderate COVID-19 in adults and paediatric patients. The monoclonal antibodies, also referred to as REGN-COV2 or as REGEN-COV2 when used i
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-